Entries by Tam

Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study

This is big news! The ability to inhibit oncogenic BRAF in PLGAs by DAY101 (formerly TAK580) was discovered right here at Dana-Farber by investigators supported by the PLGA Foundation. This therapy would not exist without the vision, determination and persistence of our team of families, donors, basic scientists, clinicians and industry. An amazing example of […]


#GearUpShowUpCare Team DFCI Lab Rats is ready to #GearUpShowUpCare See everyone at the first ever virtual Geared Up for Kids event this Sunday, May 31 at 7 PM. To join us, please register here.

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes

Dr. Mike Eck and colleagues have published their tour de force structural study of BRAF in complex with MEK and 14-3-3 dimers. This work explains longstanding questions about the biochemical behavior of BRAF and provides a foundation for understanding BRAF activation by oncogenic mutations as well as pharmacologic inhibition. Please go to: https://www.ncbi.nlm.nih.gov/pubmed/31581174 to read […]

Geared Up for Kids 2018

Team Lab Rats had so much fun this year and raised some $ too! We can’t wait to bike/run/walk again next year! In the meantime, we’ll be working hard in the lab.  

Characterizing genomic alterations in cancer by complementary functional associations

In this month’s featured publication, Drs. Hahn and Beroukhim and colleagues present REVEALER, a computational tool to investigate the functional consequences of the many mutations identified in tumor samples.  Distinguishing “driver” mutations that underlie oncogenic phenotypes from “passenger” mutations with no evident functional consequences is critical to the development of effective targeted therapies. This publication demonstrates the ability of […]